RXRX
Bearish signalScored 2026-10-12 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Recursion Pharmaceuticals, Inc.
- Nom
- Recursion Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.0B
- Employés
- 600
- PDG
- Najat Khan
- Site web
- https://www.recursion.com
- Marché
- DNLIMAZERLAY
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 127 408 titres (~546 022,38 $ US)
- Insiders
- Borgeson BlakeHERSHBERG ROBERTKhan Najat
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$643,522
Avg sell (VWAP, 90d window) $4.09 vs last close $3.47 (-15.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$643,522 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-06
- Liquidity
- Liquid $112,197,103/day · 20d vol
- Last synced
-
2026-10-16 21:10:58
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-06 | Borgeson Blake | Sell · S · 10b5-1 | 50,000 | $4.84 | $242,000 | Form 4 |
| 2026-10-06 | HERSHBERG ROBERT | Sell · S · 10b5-1 | 25,000 | $5.00 | $125,000 | Form 4 |
| 2026-09-08 | Khan Najat | Sell · S · 10b5-1 | 22,408 | $3.52 | $78,822 | Form 4 |
| 2026-09-01 | Borgeson Blake | Sell · S · 10b5-1 | 30,000 | $3.34 | $100,200 | Form 4 |
| 2026-08-04 | Borgeson Blake | Sell · S · 10b5-1 | 30,000 | $3.25 | $97,500 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-12 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
RXRX combines deeply negative fundamentals (net margin of -863%, no path to profitability) with a near-absent catalytic signal (score 15, NONE type, low confidence of 0.25), leaving no credible near-term re-rating…
The first sentence of the analysis written for RXRX on 2026-10-12 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $644K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $644K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 5.50 · operating margin -868% — readings disagree
Suggested stop 3.11, nearest stored support minus 0.5 ATR(10.3% under the last close). Reward/risk to the next stored resistance is 1.95. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -62.0% | 23.1% | 2.9% | -21.7% | 100.0% | |
| Ebit Margin | -861.1% | -787.3% | -756.7% | -603.4% | -1835.3% | |
| Ebitda Margin | -749.0% | -725.2% | -701.1% | -573.7% | -1751.2% | |
| Operating Profit Margin | -867.9% | -814.1% | -797.8% | -619.3% | -1827.8% | |
| Pretax Profit Margin | -863.5% | -789.9% | -757.0% | -603.5% | -1864.8% | |
| Continuous Operations Profit Margin | -863.4% | -788.0% | -747.7% | -603.5% | -1864.8% | |
| Net Profit Margin | -863.4% | -788.0% | -747.7% | -603.5% | -1864.8% | |
| Bottom Line Profit Margin | -863.4% | -788.0% | -747.7% | -603.5% | -1864.8% | |
| Current Ratio | 5.503 | 3.810 | 4.703 | 5.683 | 11.460 | |
| Quick Ratio | 5.503 | 3.810 | 4.703 | 5.683 | 11.460 | |
| Solvency Ratio | -1.634 | -1.032 | -1.596 | -1.057 | -2.642 | |
| Cash Ratio | 5.032 | 3.170 | 4.203 | 5.485 | 6.111 | |
| Price To Earnings Ratio | -2.840 | -4.000 | -6.241 | -5.669 | -16.314 | |
| Price To Earnings Growth Ratio | 0.192 | -0.575 | -0.386 | -0.192 | -0.163 | |
| Forward Price To Earnings Growth Ratio | 0.192 | -0.575 | -0.386 | -0.192 | -0.163 | |
| Price To Earnings Diluted Ratio | -2.840 | -4.000 | -6.241 | -5.669 | -16.314 | |
| Price To Earnings Diluted Growth Ratio | 0.192 | -0.575 | -0.386 | -0.192 | -0.163 | |
| Price To Book Ratio | 1.618 | 1.791 | 4.422 | 2.786 | 5.372 | |
| Price To Sales Ratio | 24.505 | 31.504 | 46.710 | 34.107 | 291.677 | |
| Price To Free Cash Flow Ratio | -4.838 | -4.971 | -6.824 | -11.196 | -14.701 | |
| Price To Operating Cash Flow Ratio | -4.922 | -5.161 | -7.122 | -16.204 | -18.389 | |
| Debt To Assets Ratio | 0.053 | 0.075 | 0.078 | 0.073 | 0.019 | |
| Debt To Equity Ratio | 0.069 | 0.105 | 0.109 | 0.105 | 0.021 | |
| Debt To Capital Ratio | 0.064 | 0.095 | 0.099 | 0.095 | 0.021 | |
| Long Term Debt To Capital Ratio | 0.008 | 0.018 | 0.002 | 0.001 | 0.001 | |
| Financial Leverage Ratio | 1.304 | 1.400 | 1.411 | 1.444 | 1.124 | |
| Working Capital Turnover Ratio | 0.125 | 0.135 | 0.108 | 0.083 | 0.027 | |
| Operating Cash Flow Ratio | -2.517 | -1.916 | -3.089 | -0.833 | -3.400 | |
| Operating Cash Flow Sales Ratio | -4.979 | -6.104 | -6.559 | -2.105 | -15.861 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.017 | 1.038 | 1.044 | 1.447 | 1.251 | |
| Debt Service Coverage Ratio | -51.302 | -42.572 | -2,199.761 | -1,497.796 | -57.568 | |
| Interest Coverage Ratio | -358.084 | -304.710 | -3,608.866 | -4,467.764 | -61.916 | |
| Short Term Operating Cash Flow Coverage Ratio | -40.898 | -42.632 | -7,019.024 | -861.072 | -1,762.378 | |
| Operating Cash Flow Coverage Ratio | -4.769 | -3.311 | -5.679 | -1.638 | -13.819 | |
| Capital Expenditure Coverage Ratio | -57.475 | -26.227 | -24.072 | -2.236 | -3.985 | |
| Dividend Paid And Capex Coverage Ratio | -57.475 | -26.227 | -24.072 | -2.236 | -3.985 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.082 | -3.205 | -5.554 | -3.753 | -15.093 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -62.0% | ▼-85.1% | ▼-70.5% |
| Ebit Margin | -861.1% | ▼-73.9% | ▲107.6% |
| Ebitda Margin | -749.0% | ▼-23.8% | ▲151.0% |
| Operating Profit Margin | -867.9% | ▼-53.8% | ▲117.5% |
| Pretax Profit Margin | -863.5% | ▼-73.6% | ▲112.2% |
| Continuous Operations Profit Margin | -863.4% | ▼-75.3% | ▲110.1% |
| Net Profit Margin | -863.4% | ▼-75.3% | ▲110.1% |
| Bottom Line Profit Margin | -863.4% | ▼-75.3% | ▲110.1% |
| Current Ratio | 5.503 | ▲1.693 | ▼-0.729 |
| Quick Ratio | 5.503 | ▲1.693 | ▼-0.729 |
| Solvency Ratio | -1.635 | ▼-0.602 | ▼-0.042 |
| Cash Ratio | 5.032 | ▲1.862 | ▲0.232 |
| Price To Earnings Ratio | -2.840 | ▲1.160 | ▲4.173 |
| Price To Earnings Growth Ratio | 0.192 | ▲0.766 | ▲0.417 |
| Forward Price To Earnings Growth Ratio | 0.192 | ▲0.766 | ▲0.417 |
| Price To Earnings Diluted Ratio | -2.840 | ▲1.160 | ▲4.173 |
| Price To Earnings Diluted Growth Ratio | 0.192 | ▲0.766 | ▲0.417 |
| Price To Book Ratio | 1.618 | ▼-0.173 | ▼-1.580 |
| Price To Sales Ratio | 24.505 | ▼-6.999 | ▼-61.195 |
| Price To Free Cash Flow Ratio | -4.838 | ▲0.133 | ▲3.668 |
| Price To Operating Cash Flow Ratio | -4.922 | ▲0.239 | ▲5.437 |
| Debt To Assets Ratio | 0.053 | ▼-0.022 | ▼-0.006 |
| Debt To Equity Ratio | 0.069 | ▼-0.036 | ▼-0.013 |
| Debt To Capital Ratio | 0.065 | ▼-0.030 | ▼-0.010 |
| Long Term Debt To Capital Ratio | 0.008 | ▼-0.010 | ▲0.002 |
| Financial Leverage Ratio | 1.304 | ▼-0.096 | ▼-0.033 |
| Working Capital Turnover Ratio | 0.125 | ▼-0.010 | ▲0.030 |
| Operating Cash Flow Ratio | -2.517 | ▼-0.601 | ▼-0.166 |
| Operating Cash Flow Sales Ratio | -4.979 | ▲1.126 | ▲2.143 |
| Free Cash Flow Operating Cash Flow Ratio | 1.017 | ▼-0.021 | ▼-0.142 |
| Debt Service Coverage Ratio | -51.302 | ▼-8.730 | ▲718.497 |
| Interest Coverage Ratio | -358.084 | ▼-53.374 | ▲1402.184 |
| Short Term Operating Cash Flow Coverage Ratio | -40.898 | ▲1.734 | ▲1904.303 |
| Operating Cash Flow Coverage Ratio | -4.769 | ▼-1.458 | ▲1.074 |
| Capital Expenditure Coverage Ratio | -57.475 | ▼-31.249 | ▼-34.676 |
| Dividend Paid And Capex Coverage Ratio | -57.475 | ▼-31.249 | ▼-34.676 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.082 | ▲1.123 | ▲3.855 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.83B | $1.85B | $2.05B | $1.35B | $2.92B | |
| Enterprise value | $1.16B | $1.37B | $1.71B | $854.5M | $2.64B | |
| EV / Sales | 15.60x | 23.25x | 38.94x | 21.53x | 264.31x | |
| EV / Op. cash flow | -3.13x | -3.81x | -5.94x | -10.23x | -16.66x | |
| EV / Free cash flow | -3.08x | -3.67x | -5.69x | -7.07x | -13.32x | |
| EV / EBITDA | -2.08x | -3.21x | -5.55x | -3.75x | -15.09x | |
| Net debt / EBITDA | 1.19x | 1.14x | 1.11x | 2.19x | 1.56x | |
| Current ratio | 5.50x | 3.81x | 4.70x | 5.68x | 11.46x | |
| Income quality | 0.58x | 0.78x | 0.88x | 0.35x | 0.85x | |
| Graham net-net | $1 | $1 | $1 | $2 | $3 | |
| Tax burden | 100.0% | 99.8% | 98.8% | 100.0% | 100.0% | |
| Interest burden | 100.3% | 100.3% | 100.0% | 100.0% | 101.6% | |
| Working capital | $665.1M | $526.8M | $345.0M | $469.5M | $488.1M | |
| Invested capital | $1.31B | $1.24B | $553.6M | $593.1M | $555.0M | |
| Return on assets | -43.7% | -32.0% | -50.2% | -34.1% | -30.6% | |
| Operating ROA | -44.4% | -45.6% | -51.7% | -37.5% | -40.2% | |
| Return on tangible assets | -64.3% | -48.1% | -58.0% | -34.3% | -30.7% | |
| Return on equity | -57.0% | -44.8% | -70.8% | -49.3% | -34.3% | |
| Return on invested capital | -48.1% | -37.2% | -61.0% | -40.5% | -32.3% | |
| Return on capital employed | -48.9% | -38.0% | -62.5% | -40.9% | -32.4% | |
| Earnings yield | -35.2% | -25.0% | -16.0% | -17.7% | -6.4% | |
| Free cash flow yield | -20.7% | -20.1% | -14.7% | -8.9% | -6.8% | |
| Capex / Op. cash flow | -1.7% | -3.8% | -4.2% | -44.7% | -25.1% | |
| Capex / Depreciation | 7.7% | 37.5% | 49.0% | 317.8% | 473.5% | |
| Capex / Sales | 8.7% | 23.3% | 27.2% | 94.1% | 398.0% | |
| SG&A / Sales | 236.5% | 302.8% | 252.6% | 205.6% | 576.8% | |
| R&D / Sales | 569.4% | 534.4% | 549.8% | 392.4% | 1352.7% | |
| Stock comp / Sales | 148.9% | 138.8% | 121.9% | 70.3% | 148.4% | |
| Intangibles / Total assets | 32.0% | 33.5% | 13.5% | 0.3% | 0.4% | |
| Days sales outstanding | 120d | 305d | 26d | 25d | 332d | |
| Days payables outstanding | 55d | 174d | 34d | 35d | 0d | |
| Operating cycle | 120d | 305d | 26d | 25d | 332d | |
| Cash conversion cycle | 66d | 131d | -8d | -9d | 332d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-08 Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.3% – What’s Next? Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) fell 4.3% during trading on Tuesday. The company traded as low as $4.74 and last traded at $4.5750. Approximately 14,149,966 shares traded hands during mid-day trading, a decline of 24% from the average session volume of 18,554,494 shares. The stock had previously closed at $4.78.
- 2026-10-08 Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) & Oramed Pharmaceuticals (NASDAQ:ORMP) Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and Recursion Pharmaceuticals (NASDAQ: RXRX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Institutional and Insider Ownership 12.7% of Oramed Pharmaceuticals
- 2026-10-06 Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous close.
- 2026-09-28 Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.7, indicating a -1.2% shift from the previous trading day.
- 2026-09-25 Squeeze Watch: 10 Stocks With Over 33% Short Interest Ten stocks worth more than $2 billion each have more than a third of their float sold short. At the top of the list, one company has more than 80% of its float sold short.
- 2026-09-24 Can Recursion Pharmaceuticals'' Strategic Deals Fuel Long-Term Growth? RXRX''s strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.
- 2026-09-21 Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion''s RNA Foundation Model CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion''s RNA Foundation Model. Tempus and Recursion have extended their multi-year data partnership through November 2029. The companies share a mission to use foundation models to advance precision medicine, and entered into a co.
- 2026-09-21 Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference Recursion Pharmaceuticals (NASDAQ: RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley''s Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company''s shift toward an end-to-end, AI-enabled drug discovery and development platform. Khan said the company has changed materially over the past 12 to 18 months, expanding its platform beyond biology
- 2026-09-20 Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference Recursion Pharmaceuticals NASDAQ: RXRX outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley''s Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company''s shift toward an end-to-end, AI-enabled drug discovery and development platform.
- 2026-09-16 Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.